Compare Amylx Pharmaceuticals Inc (AMLX) vs M&T Bank Corporation (MTB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs M&T Bank Corporation — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B), while M&T Bank Corporation trades at $251.93 (market cap $36.27B). The key difference: M&T Bank Corporation is far larger — about 14.3× Amylx Pharmaceuticals Inc's market cap, and M&T Bank Corporation pays a 2.39% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | MTB | |
|---|---|---|
Market Cap | $2.53B | $36.27B |
Sector | Health | Financials |
52-Week High | $24.19 | $254.04 |
52-Week Low | $7.82 | $178.63 |
Enterprise Value | $2.28B | — |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.
Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.
M&T Bank Corporation (MTB) trades at $250.45, up 0.12% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock is supported by strong fundamentals, including a net income margin of 30.85% and a P/E ratio of 13.26, indicating reasonable valuation. Recent Q2 2026 results showed record EPS of $5.35, exceeding expectations, driven by loan growth and net interest income. The consensus price target is $255.92, suggesting modest upside from current levels.
The outlook for MTB remains positive, supported by operational excellence and dividend payments, but risks include macroeconomic sensitivity and competitive pressures in regional banking. Investor sentiment is cautiously optimistic, with analysts largely holding a neutral to buy stance, while institutional ownership trends and cash flow management will be key to sustaining growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →
